Literature DB >> 22818219

The extent of perfusion deficit does not relate to the visibility of acute ischemic lesions on fluid-attenuated inversion recovery imaging.

Bastian Cheng1, Michael Rosenkranz, Anna Krützelmann, Jens Fiehler, Nils D Forkert, Christian Gerloff, Götz Thomalla.   

Abstract

OBJECTIVES: Fluid-attenuated inversion recovery imaging (FLAIR) has been suggested as a surrogate marker of lesion age in acute ischemic stroke. In a subgroup analysis, we evaluated whether the extent of perfusion deficit influences FLAIR lesion visibility and thus plays a role as a confounding variable in the interpretation of FLAIR images.
METHODS: A subgroup of patients from a previous study evaluating the use of FLAIR imaging as a surrogate marker of lesion age within the first 6 hours of ischemic stroke were examined to determine the influence of the amount of perfusion deficit on FLAIR lesion visibility.
RESULTS: N = 48 patients were included into the analysis. In positive and negative FLAIR lesion cases the extent of perfusion deficits did not differ significantly (150 mL vs. 197 mL, P = .730) nor influenced FLAIR visibility independently. In contrast, diffusion weighted imaging (DWI) lesion volumes were larger (34 mL vs. 14 mL, P = .008) and time from symptom onset longer (180 vs. 120 minute, P = .071) in FLAIR-positive cases.
CONCLUSION: Visibility of FLAIR lesions in acute stroke imaging is influenced by lesion size and time from symptom onset to MRI, but not by the amount of perfusion deficit calculated by time-to-peak (TTP) measurements.
Copyright © 2012 by the American Society of Neuroimaging.

Entities:  

Mesh:

Year:  2012        PMID: 22818219     DOI: 10.1111/j.1552-6569.2012.00708.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  1 in total

1.  Association between the perfusion/diffusion and diffusion/FLAIR mismatch: data from the AXIS2 trial.

Authors:  Anke Wouters; Patrick Dupont; Erich B Ringelstein; Bo Norrving; Angel Chamorro; Martin Grond; Rico Laage; Armin Schneider; Guido Wilms; Götz Thomalla; Robin Lemmens; Vincent N Thijs
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-03       Impact factor: 6.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.